KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Common Equity (2018 - 2025)

Vir Biotechnology's Common Equity history spans 8 years, with the latest figure at $765.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 33.48% year-over-year to $765.3 million; the TTM value through Dec 2025 reached $765.3 million, down 33.48%, while the annual FY2025 figure was $765.3 million, 33.48% down from the prior year.
  • Common Equity for Q4 2025 was $765.3 million at Vir Biotechnology, down from $796.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $2.1 billion in Q3 2022 and bottomed at $651.0 million in Q1 2021.
  • The 5-year median for Common Equity is $1.4 billion (2021), against an average of $1.4 billion.
  • The largest annual shift saw Common Equity soared 207.4% in 2022 before it tumbled 35.84% in 2025.
  • A 5-year view of Common Equity shows it stood at $1.4 billion in 2021, then soared by 45.12% to $2.1 billion in 2022, then fell by 23.47% to $1.6 billion in 2023, then decreased by 27.66% to $1.2 billion in 2024, then crashed by 33.48% to $765.3 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Common Equity are $765.3 million (Q4 2025), $796.1 million (Q3 2025), and $947.5 million (Q2 2025).